Exhibit 10.17


  


AMENDMENT TO SERIES B PREFERRED SHARE
PURCHASE AGREEMENT


 


This Amendment (this “Amendment”)
to that certain Series B Share Purchase Agreement dated as of October 4, 2017 (the “SPA”), by and between Entera
Bio Ltd., an Israeli company (the “Company”) and the Investors whose names are listed in Exhibit A therein,
is entered into as of December 18, 2017.


 


WHEREAS, the Company and
the Investors holding the majority of the Purchase Price (including by way of assignment), including D.N.A Biomedical Solutions
Ltd. wish to amend certain terms of the SPA as detailed herein;


 


NOW, THEREFORE, in consideration of the mutual
promises and covenants set forth herein, the parties hereby agree as follows:


 


All capitalized terms not otherwise defined herein
shall have the meanings ascribed to them in the SPA.


 


		1.	Notwithstanding anything to the contrary in the SPA, including Sections 1.3 and 3, the Company
may affect one or more Deferred Closings, at such date, time and place as the Company’s Board of Directors shall determine
at its sole discretion, provided that the last Deferred Closing shall occur no later than January 10, 2018.



 


		2.	Notwithstanding anything to the contrary in the SPA, the aggregate amount to be invested by Deferred
Investors at the Deferred Closings between the date hereof and January 10, 2018 shall not exceed US $1,000,000.



 


		3.	This Amendment consitutes an amendment pursuant to the provisions of Section 9.5 of the SPA. By
executing and delivering this Amendment, the Parties hereto, constituting the required majority pursuant to Section 9.5 of the
SPA, acknowledge and agree to amend the SPA as per the provisions of this Amendment with immediate effect. Except as expressly
amended under this Amendment, the terms and conditions of the SPA shall remain in full force and effect.



 


		4.	In the event of an inconsistency between this Amendment and the SPA, the terms of this Amendment
shall prevail. This Amendment shall be subject to the terms of Section 9 of the SPA (“Miscellaneous”).



 


[Remainder of Page Intentionally Left Blank
- Signature Page to Follow]


 




     


    	 	2	 



    

 


IN WITNESS WHEREOF
the parties have signed this Amendment to the Series B Preferred Share Purchase Agreement as of the date first hereinabove set
forth.


 


	The Company:	 
	 	 	 
	ENTERA BIO LTD.	 
	 	 	 
	By:	/s/ Phillip M. Schwartz	 
	Name:	Phillip M. Schwartz	 
	Title:	CEO	 


 


[Signature Page to Entera Bio Ltd. Series
B SPA Amendment]


 




     


    	 	3	 



    

  


	The Shareholder:	 
	 	 	 	 
	D.N.A. Biomedical Solutions Ltd.	 
	 	 	 	 
	By:	/s/ Yonatan Malca	  /s/ Zeev Bronfeld	 
	Name:	Yonatan Malca	Zeev Bronfeld	 
	Title:	CEO	Director	 


 


[Signature Page to Entera Bio Ltd. Series
B SPA Amendment]


 




     


    	 	4	 



    

 


	The Shareholder:	 
	 	 	 	 
	Capital Point Ltd.	 
	 	 	 	 
	By:	/s/Yossi Tamar	/s/ Shay Lior	 
	Name:	Yossi Tamar	Shay Lior	 
	Title:	CFO	CFO	 


 


[Signature Page to Entera Bio Ltd. Series
B SPA Amendment]


 




     


    	 	5	 



    

 


	The Shareholder:	 
	 	 	 
	By:	/s/ Steven Salamon	 
	Name:	Steven Salamon	 
	Title:	President, Rosalind Advisors, Inc.	 


 


(Adviser to Rosalind Capital
Partners L.P. & Rosalind Master Fund L.P.)


 


[Signature Page to Entera Bio Ltd. Series
B SPA Amendment]


 




     


    	 	6	 



    

 


	The Shareholder:	 
	 	 	 
	By:	/s/ Lars Bader	 
	Name:	Lars Bader	 
	Title:	 	 


 


[Signature Page to Entera Bio Ltd. Series
B SPA Amendment]


 




     


    	 	7	 



    

 


	The Shareholder:	 
	 	 	 
	Centillion Fund	 
	 	 	 
	By:	/s/ Sean Ellis	 
	Name:	Sean Ellis	 
	Title:	C/O	 


 


[Signature Page to Entera Bio Ltd. Series
B SPA Amendment]